# A Study to Evaluate the Efficacy and Safety of the Combination of Glumetinib and Docetaxel（Albumin Bound）Verse Docetaxel for the Treatment of MET-overexpressed

Source: https://onco.cc/trials/nct06525350/  
OnCo record `nct06525350` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of docetaxel in lung cancer, run by CSPC ZhongQi Pharmaceutical Technology Co., Ltd., not yet recruiting.

## Summary

A Study to Evaluate the Efficacy and Safety of the Combination of Glumetinib and Docetaxel（Albumin Bound）Verse Docetaxel for the Treatment of MET-overexpressed Non-small Cell Lung Cancer is a phase 2, randomised interventional study registered as NCT06525350 by CSPC ZhongQi Pharmaceutical Technology Co., Ltd., with a registry enrolment figure of 256 participants, started 2024-07 and due to reach its primary completion in 2026-12-25. Interventions recorded: Glumetinib tablets; HB1801 (docetaxel, albumin-bound）; Docetaxel. Conditions listed: Locally Advanced/Recurrent or Distant Metastasized Non-small Cell Lung Cancer With MET Overexpression. Primary outcome: Dose-limiting toxicity(DLT) occurrence and incidence; Recommended phase 2 dose(RP2D) of the combination therapy; Adverse events (AE) and serious adverse events (SAE) occurrence and incidence. Lung eligibility wording from the registry: "Unresectable locally advanced or metastatic non-small cell lung cancer (IIIB, IIIC, or IV according to the 8th edition TNM staging standards of IASLC) confirmed by histology or cytology;". No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-09-25
- Tags: ctgov-ingest; lung-deep-dive
- Registry id: NCT06525350
- Phase: 2
- Setting: A Randomized, Controlled, Open-label Phase II Study to Evaluate the Safety, Tolerability, and Efficacy of the Combination of Glumetinib Tablets and Docetaxel for Injection（Albumin Bound）Verse Docetaxel in the Treatment of Locally Advanced/Recurrent or Distant Metastasized Non-small Cell Lung Cancer Patients With MET Overexpression
- Sponsor: CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
- Enrolled: 256

## Sources

- ClinicalTrials.gov NCT06525350: https://clinicaltrials.gov/study/NCT06525350

## Connected records

- cancers: [MET exon 14 and MET-amplified non-small-cell lung cancer](https://onco.cc/cancers/met-altered-nsclc/), [Unresectable stage III non-small-cell lung cancer](https://onco.cc/cancers/stage-iii-unresectable-nsclc/)
- technologies: [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/)
- drugs: [Docetaxel](https://onco.cc/drugs/docetaxel/)
- terms: [Lung cancer trials open today (registry snapshot)](https://onco.cc/terms/lung-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct06525350.json